The 4th AsiaTIDES annuel conference, being held in Tokyo, Japan from February 28 to March 1, 2012, continues to be the premier forum to get a comprehensive update, meet key players and increase knowledge of the oligonucleotide- and peptide-based therapeutics fields. The faculty list for the 2012 program has more representation from big pharma such as Merck, Genzyme, and GlaxoSmithKline. Projects and presentations will be heard from Isis, Novo Nordisk, Ipsen, Quark, Alnylam, Santaris, Tekmira, etc. among other important companies. This year’s AsiaTIDES focuses on providing an in-depth tutorials to acknowledge the technical and regulatory aspects of peptide specifications and characterization, as well as the strategies and approaches for in vivo Delivery of Oligonucleotides.

Dr. Patrick Lu, President and CEO of Sirnaomics, Inc., will give a presentation entitled Developing siRNA Therapeutics for Clinical Studies in China, on the March 1st afteroon forum.

In his presentation, Dr. Lu will introduce how Sirnaomics has been learning from the occurrences of more than two dozen clinical studies globally, and how the company is pushing forward assiduously of their two siRNA therapeutic product candidates, STP705 for Scarless Skin Wound Healing and STP601 for Diabetic Ocular disease, for clinical studies in China. In the past 4 years since Sirnaomics was established in Maryland, USA, the company has been working closely with the pharma sponsors, CMC vendors, pre-clinical and clinical CROs, and China’s SFDA, to carry on its multiple-targeted siRNA therapeutical programs. The company is aiming to enter into clinical study for their siRNA therapeutic candidates in 2012.